PharmaSGP Holding SE Cash Flow Conversion Efficiency
PharmaSGP Holding SE cash flow conversion efficiency. Based on the latest financial reports, PharmaSGP Holding SE (PSG) has a cash flow conversion efficiency ratio of 0.115x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€4.22 Million ≈ $4.94 Million USD) by net assets (€36.67 Million ≈ $42.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PharmaSGP Holding SE (2014–2024)
Cash flow conversion efficiency of PharmaSGP Holding SE from 2014 to 2024. This chart illustrates how PharmaSGP Holding SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PSG stock price and chart for real-time trading data and today's change.
PharmaSGP Holding SE Cash Flow Conversion Ratio Explained
PharmaSGP Holding SE cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PharmaSGP Holding SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PharmaSGP Holding SE ranked by their cash flow conversion efficiency. Also see PSG market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Smartwin Electronics Technology Co.Ltd.
SHE:301106
|
N/A |
|
Ind-Swift Laboratories Limited
NSE:INDSWFTLAB
|
-0.015x |
|
Hangzhou Heshun Technology Co.LTD.
SHE:301237
|
N/A |
|
Baader Bank Aktiengesellschaft
F:BWB
|
N/A |
|
Paz Corp
SN:PAZ
|
-0.032x |
|
Fullink Technology Co. LTD.
SHE:301067
|
N/A |
|
Leadtek Research Inc
TW:2465
|
-0.212x |
|
Sofwave Medical Ltd
TA:SOFW
|
-0.014x |
Annual Cash Flow Conversion Efficiency for PharmaSGP Holding SE (2014–2024)
The table below shows the annual cash flow conversion efficiency of PharmaSGP Holding SE from 2014 to 2024. Review PharmaSGP Holding SE free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €31.96 Million ≈ $37.37 Million |
€24.88 Million ≈ $29.08 Million |
0.778x | +16.15% |
| 2023-12-31 | €39.75 Million ≈ $46.48 Million |
€26.64 Million ≈ $31.14 Million |
0.670x | -15.68% |
| 2022-12-31 | €31.10 Million ≈ $36.36 Million |
€24.71 Million ≈ $28.89 Million |
0.795x | +44.12% |
| 2021-12-31 | €22.20 Million ≈ $25.95 Million |
€12.24 Million ≈ $14.31 Million |
0.551x | -58.95% |
| 2020-12-31 | €11.51 Million ≈ $13.45 Million |
€15.46 Million ≈ $18.07 Million |
1.343x | +628.25% |
| 2019-12-31 | €95.58 Million ≈ $111.74 Million |
€17.63 Million ≈ $20.61 Million |
0.184x | -20.63% |
| 2017-12-31 | €61.32 Million ≈ $71.68 Million |
€14.25 Million ≈ $16.66 Million |
0.232x | +276.99% |
| 2016-12-31 | €57.53 Million ≈ $67.26 Million |
€3.55 Million ≈ $4.15 Million |
0.062x | -68.67% |
| 2015-12-31 | €53.79 Million ≈ $62.88 Million |
€10.59 Million ≈ $12.38 Million |
0.197x | +75.71% |
| 2014-12-31 | €48.27 Million ≈ $56.43 Million |
€5.41 Million ≈ $6.32 Million |
0.112x | -- |
About PharmaSGP Holding SE
PharmaSGP Holding SE manufactures and sells over-the-counter drugs and other healthcare products in Germany. The company's pharmaceutical products include Baldriparan for the treatment of sleep disorders; Spalt, Formigran, and Kamol massage creams for the treatment of various pain conditions; RubaXX pharmaceutical drops for the treatment of rheumatic pain in bones, tendons, and muscles; Restaxil … Read more